Press Releases

Jun. 12 Alnylam to Host Tenth “RNAi Roundtable” Webcast Series BU
Jun. 03 Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics BU
May. 19 Alnylam Issues 2025 Corporate Responsibility Report BU
May. 19 Alnylam Pharmaceuticals : 2025 REPORT PU
May. 12 New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden BU
May. 07 Alnylam to Webcast Presentations at Upcoming Investor Conferences BU
May. 04 Alnylam Pharmaceuticals : Q1 2026 Presentation › PU
May. 04 Alnylam Pharmaceuticals : Q1 2026 GAAP/Non-GAAP Reconciliation › PU
May. 04 Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM BU
Apr. 30 Alnylam: Q1 Earnings Snapshot AQ
Apr. 30 Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress BU
Apr. 16 Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results BU
Mar. 30 New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management BU
Mar. 24 Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association BU
Mar. 10 Alnylam to Webcast TTR Investor Webinar BU
Mar. 05 Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics AQ
Feb. 23 Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference BU
Feb. 12 Alnylam Pharmaceuticals : Q4 2025 Earnings Presentation › PU
Feb. 12 Alnylam: Q4 Earnings Snapshot AQ
Feb. 12 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress BU
Jan. 29 Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results BU
Jan. 12 Alnylam Pharmaceuticals : 2026 J.P. Morgan Presentation PU
Jan. 11 Alnylam Pharmaceuticals : Launches “ 2030” Strategy to Drive Next Era of Growth and Patient Impact PU
Jan. 11 Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact BU
Jan. 05 Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference BU
No results match your criteria
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!